{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T08:40:35Z","timestamp":1782549635145,"version":"3.54.5"},"reference-count":69,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Carreras Leukemia foundation","award":["AH06-01"],"award-info":[{"award-number":["AH06-01"]}]},{"name":"CSC scholarship","award":["AH06-01"],"award-info":[{"award-number":["AH06-01"]}]},{"name":"Philipps University of Marburg","award":["AH06-01"],"award-info":[{"award-number":["AH06-01"]}]},{"name":"Open Acess Publication Fund of Philipps-Universitat Marburg","award":["AH06-01"],"award-info":[{"award-number":["AH06-01"]}]},{"name":"Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)","award":["AH06-01"],"award-info":[{"award-number":["AH06-01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Current standard adjuvant therapy of glioblastoma multiforme (GBM) using temozolomide (TMZ) frequently fails due to therapy resistance. Thus, novel therapeutic approaches are highly demanded. We tested the therapeutic efficacy of the second-generation XPO1 inhibitor Eltanexor using assays for cell viability and apoptosis in GBM cell lines and GBM stem-like cells. For most GBM-derived cells, IC50 concentrations for Eltanexor were below 100 nM. In correlation with reduced cell viability, apoptosis rates were significantly increased. GBM stem-like cells presented a combinatorial effect of Eltanexor with TMZ on cell viability. Furthermore, pretreatment of GBM cell lines with Eltanexor significantly enhanced radiosensitivity in vitro. To explore the mechanism of apoptosis induction by Eltanexor, TP53-dependent genes were analyzed at the mRNA and protein level. Eltanexor caused induction of TP53-related genes, TP53i3, PUMA, CDKN1A, and PML on both mRNA and protein level. Immunofluorescence of GBM cell lines treated with Eltanexor revealed a strong accumulation of CDKN1A, and, to a lesser extent, of p53 and Tp53i3 in cell nuclei as a plausible mechanism for Eltanexor-induced apoptosis. From these data, we conclude that monotherapy with Eltanexor effectively induces apoptosis in GBM cells and can be combined with current adjuvant therapies to provide a more effective therapy of GBM.<\/jats:p>","DOI":"10.3390\/biomedicines10092145","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T23:53:21Z","timestamp":1661990001000},"page":"2145","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide"],"prefix":"10.3390","volume":"10","author":[{"given":"Katharina","family":"Otte","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany"},{"name":"Department of Hematology, Oncology & Immunology, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madita","family":"Braun","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany"},{"name":"Department of Hematology, Oncology & Immunology, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Neubauer","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology & Immunology, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmann","family":"Raifer","sequence":"additional","affiliation":[{"name":"FACS Core Facility, Philipps University Marburg, Hans-Meerwein-Strasse 3, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Helmprobst","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Ovalle","family":"Barrera","sequence":"additional","affiliation":[{"name":"Department of Neuropathology, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-9410","authenticated-orcid":false,"given":"Christopher","family":"Nimsky","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2773-3357","authenticated-orcid":false,"given":"J\u00f6rg W.","family":"Bartsch","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tillmann","family":"Rusch","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology & Immunology, Philipps University Marburg, Baldingerstrasse, 35043 Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","article-title":"CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006\u20132010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro-Oncology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/cncr.30023","article-title":"Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009","volume":"122","author":"Gramatzki","year":"2016","journal-title":"Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Rajaratnam, V., Islam, M.M., Yang, M., Slaby, R., Ramirez, H.M., and Mirza, S.P. (2020). Glioblastoma: Pathogenesis and current status of chemotherapy and other novel treatments. Cancers, 12.","DOI":"10.3390\/cancers12040937"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1158\/1055-9965.EPI-14-0275","article-title":"Epidemiologic and molecular prognostic review of glioblastoma","volume":"23","author":"Thakkar","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1634\/theoncologist.2009-0291","article-title":"Review on quality of life issues in patients with primary brain tumors","volume":"15","author":"Taphoorn","year":"2010","journal-title":"Oncologist"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1200\/JCO.2017.73.0119","article-title":"Adult Glioblastoma","volume":"35","author":"Alexander","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3322\/caac.21613","article-title":"Management of glioblastoma: State of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"695325","DOI":"10.3389\/fcell.2021.695325","article-title":"Critical View of Novel Treatment Strategies for Glioblastoma: Failure and Success of Resistance Mechanisms by Glioblastoma Cells","volume":"9","author":"Burster","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Dymova, M.A., Kuligina, E.V., and Richter, V.A. (2021). Molecular Mechanisms of Drug Resistance in Glioblastoma. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22126385"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.drup.2018.03.003","article-title":"Glioblastoma cancer stem cell biology: Potential theranostic targets","volume":"42","author":"Sharifzad","year":"2019","journal-title":"Drug Resist. Updates"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhao, K., Sch\u00e4fer, A., Zhang, Z., Els\u00e4sser, K., Culmsee, C., Zhong, L., Pagenstecher, A., Nimsky, C., and Bartsch, J.W. (2022). Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010157"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nri3086","article-title":"Microglial cell origin and phenotypes in health and disease","volume":"11","author":"Saijo","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"285246","DOI":"10.1155\/2013\/285246","article-title":"The controversial role of microglia in malignant gliomas","volume":"2013","author":"Wei","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"ref_16","first-page":"395","article-title":"Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours","volume":"39","author":"Roszman","year":"1980","journal-title":"Clin. Exp. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1084\/jem.136.6.1631","article-title":"Depressed cell-mediated immunity in patients with primary intracranial tumours","volume":"136","author":"Brooks","year":"1972","journal-title":"J. Exp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","article-title":"Regulatory T cells, tumour immunity and immunotherapy","volume":"6","author":"Zou","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fonc.2015.00153","article-title":"Immunosuppressive mechanisms of malignant gliomas: Parallels at Non-CNS sites","volume":"5","author":"Perng","year":"2015","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.4049\/jimmunol.132.4.1837","article-title":"Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects","volume":"132","author":"Fontana","year":"1984","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/eji.1830180416","article-title":"The glioblastoma-derived T cell suppressor factor\/transforming growth factor-beta 2 inhibits T cell growth without affecting the interaction of interleukin 2 with its receptor","volume":"18","author":"Siepl","year":"1988","journal-title":"Eur. J. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1227\/NEU.0b013e3181fa775b","article-title":"A systematic review of the literature on the effects of dexamethasone on the brain from in vivo human-based studies: Implications for physiological brain imaging of patients with intracranial tumors","volume":"67","author":"Kotsarini","year":"2010","journal-title":"Neurosurgery"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Adhikaree, J., Moreno-Vicente, J., Kaur, A.P., Jackson, A.M., and Patel, P.M. (2020). Resistance Mechanisms and Barriers to Successful Immunotherapy for Treating Glioblastoma. Cells, 9.","DOI":"10.3390\/cells9020263"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/stem.2703","article-title":"Genetic Evolution of Glioblastoma Stem-Like Cells from Primary to Recurrent Tumor","volume":"35","author":"Orzan","year":"2017","journal-title":"Stem Cells"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s00401-013-1196-4","article-title":"Glioblastomas are composed of genetically divergent clones with distinct tumorigenic potential and variable stem cell-associated phenotypes","volume":"127","author":"Stieber","year":"2014","journal-title":"Acta Neuropathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2009.04.045","article-title":"Virotherapy against malignant glioma stem cells","volume":"289","author":"Dey","year":"2010","journal-title":"Cancer Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1101\/gad.261982.115","article-title":"Cancer stem cells in glioblastoma","volume":"29","author":"Lathia","year":"2015","journal-title":"Genes Dev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1038\/onc.2016.85","article-title":"A comprehensive profile of recurrent glioblastoma","volume":"35","author":"Campos","year":"2016","journal-title":"Oncogene"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1080\/17425247.2017.1263615","article-title":"Cancer stem cell-targeted therapeutics and delivery strategies","volume":"14","author":"Ahmad","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_30","first-page":"277","article-title":"Apoptosis in radiation therapy: A double-edged sword","volume":"34","year":"2012","journal-title":"Exp. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bjc.6600711","article-title":"Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids","volume":"88","author":"Pawlak","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Strobel, H., Baisch, T., Fitzel, R., Schilberg, K., Siegelin, M.D., Karpel-Massler, G., Debatin, K.M., and Westhoff, M.A. (2019). Temozolomide and Other Alkylating Agents in Glioblastoma Therapy. Biomedicines, 7.","DOI":"10.3390\/biomedicines7030069"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Beltzig, L., Schwarzenbach, C., Leukel, P., Frauenknecht, K.B.M., Sommer, C., Tancredi, A., Hegi, M.E., Christmann, M., and Kaina, B. (2022). Senescence Is the Main Trait Induced by Temozolomide in Glioblastoma Cells. Cancers, 14.","DOI":"10.3390\/cancers14092233"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Schwarzenbach, C., Tatsch, L., Brandstetter Vilar, J., Rasenberger, B., Beltzig, L., Kaina, B., Tomicic, M.T., and Christmann, M. (2021). Targeting c-IAP1, c-IAP2, and Bcl-2 Eliminates Senescent Glioblastoma Cells Following Temozolomide Treatment. Cancers, 13.","DOI":"10.3390\/cancers13143585"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.tcb.2007.02.003","article-title":"CRM1-mediated nuclear export: To the pore and beyond","volume":"17","author":"Hutten","year":"2007","journal-title":"Trends Cell Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-020-00903-4","article-title":"XPO1-dependent nuclear export as a target for cancer therapy","volume":"13","author":"Azizian","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1007\/s00018-010-0325-7","article-title":"Nuclear transport and the mitotic apparatus: An evolving relationship","volume":"67","author":"Wozniak","year":"2010","journal-title":"Cell Mol. Life Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ceb.2015.04.012","article-title":"Nuclear transport factors: Global regulation of mitosis","volume":"35","author":"Forbes","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e11466","DOI":"10.7554\/eLife.11466","article-title":"A deep proteomics perspective on CRM1-mediated nuclear export and nucleocytoplasmic partitioning","volume":"4","author":"Kirli","year":"2015","journal-title":"eLife"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1091\/mbc.e07-10-1050","article-title":"Localized RanGTP accumulation promotes microtubule nucleation at kinetochores in somatic mammalian cells","volume":"19","author":"Torosantucci","year":"2008","journal-title":"Mol. Biol. Cell."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bbrc.2009.04.154","article-title":"A fraction of Crm1 locates at centrosomes by its CRIME domain and regulates the centrosomal localization of pericentrin","volume":"384","author":"Liu","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"101179","DOI":"10.1016\/j.tranon.2021.101179","article-title":"Antitumor efficacy of XPO1 inhibitor Selinexor in KRAS-mutant lung adenocarcinoma patient-derived xenografts","volume":"14","author":"Rosen","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Birnbaum, D.J., Finetti, P., Birnbaum, D., Mamessier, E., and Bertucci, F. (2019). XPO1 expression is a poor-prognosis marker in pancreatic adenocarcinoma. J. Clin. Med., 8.","DOI":"10.3390\/jcm8050596"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.21037\/tcr-21-1646","article-title":"Pan-cancer analysis reveals the roles of XPO1 in predicting prognosis and tumorigenesis","volume":"10","author":"Zhao","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1093\/annonc\/mdu338.14","article-title":"Preclinical and Early Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (Sine) Exportin 1 (Xpo1) Antagonist Selinexor (Kpt-330) in Patients (Pts) with Platinum Resistant\/Refractory Ovarian Cancer (Ovca)","volume":"32","author":"Martignetti","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.21037\/sci.2019.02.03","article-title":"The past, present, and future of CRM1\/XPO1 inhibitors","volume":"6","author":"Wang","year":"2019","journal-title":"Stem Cell Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature19771","article-title":"XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer","volume":"538","author":"Kim","year":"2016","journal-title":"Nature"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","article-title":"Nucleo-cytoplasmic transport as a therapeutic target of cancer","volume":"7","author":"Gravina","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/neuonc\/nou303","article-title":"Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma","volume":"17","author":"Green","year":"2015","journal-title":"Neuro Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2040620720930629","DOI":"10.1177\/2040620720930629","article-title":"Selinexor in relapsed\/refractory multiple myeloma","volume":"11","author":"Richter","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"iii716","DOI":"10.1093\/annonc\/mdy424.024","article-title":"Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC)","volume":"29","author":"Hays","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1002\/ajh.26420","article-title":"A phase 1 clinical trial of oral Eltanexor in patients with relapsed or refractory multiple myeloma","volume":"97","author":"Cornell","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1182\/blood-2019-124136","article-title":"Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome","volume":"34","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1158\/1538-7445.AM2020-4181","article-title":"Abstract 4181: The XPO1 inhibitor, Eltanexor, exhibits potent in vivo activity against a broad range of pediatric acute lymphoblastic leukemia subtypes","volume":"80","author":"Lock","year":"2020","journal-title":"Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1200\/JCO.2019.37.15_suppl.2005","article-title":"Efficacy and safety of selinexor in recurrent glioblastoma","volume":"37","author":"Lassman","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1158\/1078-0432.CCR-21-2225","article-title":"A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma","volume":"28","author":"Lassman","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Hannen, R., Selmansberger, M., Hauswald, M., Pagenstecher, A., Nist, A., Stiewe, T., Acker, T., Carl, B., Nimsky, C., and Bartsch, J.W. (2019). Comparative Transcriptomic Analysis of Temozolomide Resistant Primary GBM Stem-Like Cells and Recurrent GBM Identifies Up-Regulation of the Carbonic Anhydrase CA2 Gene as Resistance Factor. Cancers, 11.","DOI":"10.3390\/cancers11070921"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Thome, I., Lacle, R., Vo\u00df, A., Bortolussi, G., Pantazis, G., Schmidt, A., Conrad, C., Jacob, R., Timmesfeld, N., and Bartsch, J.W. (2020). Neoplastic Cells are the Major Source of MT-MMPs in IDH1-Mutant Glioma, Thus Enhancing Tumor-Cell Intrinsic Brain Infiltration. Cancers, 12.","DOI":"10.3390\/cancers12092456"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e80","DOI":"10.1002\/cpsc.80","article-title":"Isolation of Neural Stem Cells from Whole Brain Tissues of Adult Mice","volume":"49","author":"Deshpande","year":"2019","journal-title":"Curr. Protoc. Stem Cell Biol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Cook, L., Sengelmann, M., Winkler, B., Nagl, C., Koch, S., Schlomann, U., Slater, E.P., Miller, M.A., von Strandmann, E.P., and D\u00f6rsam, B. (2022). ADAM8-Dependent Extracellular Signaling in the Tumor Microenvironment Involves Regulated Release of Lipocalin 2 and MMP-9. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23041976"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/onc.2010.413","article-title":"p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation","volume":"30","author":"Xia","year":"2011","journal-title":"Oncogene"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Solozobova, V., Rolletschek, A., and Blattner, C. (2009). Nuclear accumulation and activation of p53 in embryonic stem cells after DNA damage. BMC Cell Biol., 10.","DOI":"10.1186\/1471-2121-10-46"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41420-021-00442-y","article-title":"Germline mutations in apoptosis pathway genes in ovarian cancer; the functional role of a TP53I3 (PIG3) variant in ROS production and DNA repair","volume":"7","author":"Chaudhry","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1158\/1535-7163.MCT-17-1303","article-title":"The XPO1 Inhibitor Selinexor Inhibits Translation and Enhances the Radiosensitivity of Glioblastoma Cells Grown In Vitro and In Vivo","volume":"17","author":"Wahba","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/leu.2016.145","article-title":"KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells","volume":"31","author":"Etchin","year":"2017","journal-title":"Leukemia"},{"key":"ref_66","first-page":"3134","article-title":"Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Refractory Multiple Myeloma","volume":"130","author":"Cornell","year":"2017","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/leu.2016.136","article-title":"Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies","volume":"30","author":"Hing","year":"2016","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jconrel.2020.09.002","article-title":"Advances in drug delivery technology for the treatment of glioblastoma multiforme","volume":"328","author":"Cha","year":"2020","journal-title":"J. Control. Release"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/9\/2145\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:21:17Z","timestamp":1760142077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/9\/2145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":69,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["biomedicines10092145"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10092145","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]}}}